Alnylam to Host Third Annual "RNAi Roundtable" Webcast Series
July 12 2016 - 8:00AM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, today announced that it plans to host its 3rd
Annual series of webcast "RNAi Roundtables" this summer and early
fall. The 2016 series will consist of presentations from Alnylam
scientists, clinical collaborators, and patients or patient
advocates, who will review recent progress in many of the Company's
development-stage pipeline programs. Each event will be webcast
live on the Investors page of the Company's website,
www.alnylam.com, and a replay of the roundtables will be posted on
the Alnylam website approximately three hours after each event.
The first roundtable of the series will focus on patisiran and
revusiran for the treatment of hereditary transthyretin-mediated
amyloidosis (hATTR amyloidosis). This event will take place on
Wednesday, July 20, 11:30 a.m. - 1:00 p.m. ET. Featured speakers
include:
- Eric Green, Vice President, General
Manager, TTR Program
- Jared Gollob, M.D., Vice President,
Clinical Research
- Guest Speaker: John L. Berk, M.D.,
Director, Clinical Trials for Familial Amyloidosis and Director,
Localized Amyloid Clinic, Boston University Amyloidosis Center
- Guest Speaker: Christina Lindsey,
Patient living with hATTR amyloidosis
The second roundtable will focus on fitusiran for the treatment
of hemophilia and rare bleeding disorders. This event will take
place on Monday, August 22, 10:30 a.m. - 12:00 p.m. ET. Featured
speakers include:
- Akin Akinc, Ph.D., Vice President,
General Manager, Fitusiran Program
- Benny Sorensen, M.D., Ph.D., Medical
Director, Clinical Development
- Guest Speaker: Brian O’Mahony, Chief
Executive, Irish Haemophilia Society Ltd. and person living with
severe hemophilia B
Alnylam has scheduled additional RNAi Roundtables in the coming
months focused on some of its other clinical programs, including:
ALN-CC5 for the treatment of complement-mediated diseases,
ALN-AS1 for the treatment of acute hepatic porphyrias, ALN-GO1 for
the treatment of primary hyperoxaluria type 1 and ALN-HBV for the
treatment of hepatitis B virus infection.
Additional details for the rest of the RNAi Roundtables,
including speakers, dates and times will be provided on the Capella
section of the Company's website, www.alnylam.com/capella.
About RNAiRNAi (RNA interference) is a revolution in
biology, representing a breakthrough in understanding how genes are
turned on and off in cells, and a completely new approach to drug
discovery and development. Its discovery has been heralded as "a
major scientific breakthrough that happens once every decade or
so," and represents one of the most promising and rapidly advancing
frontiers in biology and drug discovery today which was awarded the
2006 Nobel Prize for Physiology or Medicine. RNAi is a natural
process of gene silencing that occurs in organisms ranging from
plants to mammals. By harnessing the natural biological process of
RNAi occurring in our cells, the creation of a major new class of
medicines, known as RNAi therapeutics, is on the horizon. Small
interfering RNA (siRNA), the molecules that mediate RNAi and
comprise Alnylam's RNAi therapeutic platform, target the cause of
diseases by potently silencing specific mRNAs, thereby preventing
disease-causing proteins from being made. RNAi therapeutics have
the potential to treat disease and help patients in a fundamentally
new way.
About Alnylam PharmaceuticalsAlnylam is a
biopharmaceutical company developing novel therapeutics based on
RNA interference, or RNAi. The company is leading the translation
of RNAi as a new class of innovative medicines. Alnylam's pipeline
of investigational RNAi therapeutics is focused in 3 Strategic
Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline
of RNAi therapeutics for the treatment of rare diseases;
Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics
toward genetically validated, liver-expressed disease targets for
unmet needs in cardiovascular and metabolic diseases; and Hepatic
Infectious Disease, with a pipeline of RNAi therapeutics that
address the major global health challenges of hepatic infectious
diseases. In early 2015, Alnylam launched its "Alnylam 2020"
guidance for the advancement and commercialization of RNAi
therapeutics as a whole new class of innovative medicines.
Specifically, by the end of 2020, Alnylam expects to achieve a
company profile with 3 marketed products, 10 RNAi therapeutic
clinical programs – including 4 in late stages of development –
across its 3 STArs. The company's demonstrated commitment to RNAi
therapeutics has enabled it to form major alliances with leading
companies including Ionis, Novartis, Roche, Takeda, Merck,
Monsanto, The Medicines Company, and Sanofi Genzyme. In addition,
Alnylam holds an equity position in Regulus Therapeutics Inc., a
company focused on discovery, development, and commercialization of
microRNA therapeutics. Alnylam scientists and collaborators have
published their research on RNAi therapeutics in over 200
peer-reviewed papers, including many in the world's top scientific
journals such as Nature, Nature Medicine, Nature Biotechnology,
Cell, New England Journal of Medicine, and The Lancet. Founded in
2002, Alnylam maintains headquarters in Cambridge, Massachusetts.
For more information about Alnylam's pipeline of investigational
RNAi therapeutics, please visit www.alnylam.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160712005405/en/
Alnylam Pharmaceuticals, Inc.(Investors and Media)Christine
Regan Lindenboom, 617-682-4340or(Investors)Josh Brodsky,
617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Sep 2023 to Sep 2024